KN2

• CAT Number: I030116
• Molecular Formula: C23H22Br4Cl2N4O2
• Molecular Weight: 776.97
• Purity: 98%
• Synonyms: KN2; KN 2; KN-2
• Solubility: To be determined
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N1-(3,4-dichlorophenethyl)-N4-(4-(4,5,6,7-tetrabromo-1H-benzo[d]imidazol-1-yl)butyl)succinamide
• InChI: InChI=1S/C23H22Br4Cl2N4O2/c24-18-19(25)21(27)23-22(20(18)26)32-12-33(23)10-2-1-8-30-16(34)5-6-17(35)31-9-7-13-3-4-14(28)15(29)11-13/h3-4,11-12H,1-2,5-10H2,(H,30,34)(H,31,35)
• InChIKey: HHGOOXRIHBVNFX-UHFFFAOYSA-N
• SMILES: O=C(NCCC1=CC=C(Cl)C(Cl)=C1)CCC(NCCCCN2C=NC3=C(Br)C(Br)=C(Br)C(Br)=C23)=O

KN2(CAT: I030116) is a bivalent and highly selective inhibitor of casein kinase 2 (CK2), widely utilized in cell signaling and cancer research. With low nanomolar affinity and cell permeability, KN2 effectively binds to CK2 and suppresses the intracellular phosphorylation of CK2 substrates, making it a valuable tool for studying CK2-mediated signaling pathways. Kinase profiling highlights its strong selectivity, attributed to its interaction with the αD pocket, underscoring its utility in reducing off-target effects. KN2 is critical for preclinical studies exploring CK2’s role in tumor progression, cellular regulation, and the development of targeted therapies for CK2-driven diseases.